The AMÜP study for drug surveillance in psychiatry - A summary of inpatient data

Pharmacopsychiatry

Volumn 37, Issue SUPPL. 1, 2004, Pages

  Grohmann, R ^a   Hippius, H ^a   Helmchen, H ^b   Ruther E ^c   Schmidt, L G ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CLOMIPRAMINE; CLOZAPINE; DIAZEPAM; DOXEPIN; FLURAZEPAM; FLUSPIRILENE; HALOPERIDOL; HYPNOTIC AGENT; LEVOMEPROMAZINE; LITHIUM SALT; LORAZEPAM; MAPROTILINE; NEUROLEPTIC AGENT; PERAZINE; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRANQUILIZER; TRANYLCYPROMINE;

ADDICTION; ADULT; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; EEG ABNORMALITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HUMAN; HYPERHIDROSIS; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MANIA; MENTAL DISEASE; MENTAL HOSPITAL; MICTURITION DISORDER; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUROSIS; NEUTROPENIA; PARANOIA; PARKINSONISM; PATIENT COMPLIANCE; PERSONALITY DISORDER; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SUICIDAL BEHAVIOR; TREMOR; URINARY TRACT DISEASE; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG INTERACTION; METHODOLOGY; POSTMARKETING SURVEILLANCE; PSYCHIATRY; TIME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRY; PSYCHOTROPIC DRUGS; TIME FACTORS;

EID: 2442697568     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ananth JV, Ban TA, Lehmann HE, Rivzi FA. An adverse reaction unit: results and functions. Am J Psychiat 1971; 127: 1339-1344
2. Brenner PM, Wolf B, Grohmann R, Rüther E. Benzodiazepine dependence - aetiological factors, time course, consequences and withdrawal symptomatology: a study of five cases. Drug Alcohol Depend 1988; 22: 253-261
3. Bürke H, Grohmann R, Rüther E. Drug surveillance/drug monitoring in psychiatric outpatient treatment: Prescription of psychotropic drugs, diagnosis and adverse drug reaction - 3 years. Pharmacopsych 1988; 21: 293-294
4. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993; 16: 589-610
5. Dirschedl P, Hasford J. Drug monitoring of psychiatric patients: Mathodological aspects. Pharmacopsych 1985; 18: 27-28
6. Dirschedl P, Grohmann R, Schmidt LG. Reliability of adverse drug reactions assessment. Pharmacopsych 1986; 19: 292-293
7. Dirschedl P, Grohmann R. Exploring heterogeneous risk structures: Comparison of a bootstrapped model selection and nonparametric classification technique. In: Jöckel KH, Rothe G, Sendler W [eds]. Boot-strapped and related techniques. Trier, FRG. 1990. proceedings Springer, Berlin Heidelberg New York Tokyo: 1992: 189-195
8. Gerz HJ, Schmidt LG. Low Melanin content of substantia nigra in a case of neuroleptic malignant syndrome. Pharmacopsch 1991; 24: 93-95
9. Grohmann R, Hippius H, Müller-Oerlingheusen B et al. Assesment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol 1984; 26: 727-734
10. Grohmann R, Dirschedl P, Scherer J, Schmidt LG, Wunderlich O. Reliability of adverse drug reaction assessment in psychiatric inpatients. Eur Arch Psychiatry Neurol Sci 1985; 235: 158-163
11. Grohmann R, Dirschedl P, Rennig E, Scherer J, Schmidt LG. Methodological problems in assessment of adverse drug reactions with drug combinations. Pharmacopsychiat 1986; 19: 300-301
12. Grohmann R, Rüther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 1989; 99: 101-104
13. Grohmann R, Schmidt LG, Spieß-Kiefer C, Rüther E. Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program. Psychopharmacol 1989; 99: 109-112
14. Grohmann R, Schmidt LG, Rühter E. Drug surveillance in psychiatric patients in the FRG. In: Bunney EW, Hippius H, Laakmann G, Schmauss M. [eds]. Proceedings of the 16th C.I.N.P.-Congress Springer, Berlin Heidelberg New York Tokyo: 1990: 590-597
15. Grohmann R, Ströbel C, Rüther E, Dirschedl P, Helmchen H, Hippius H, Müller- Oerlinghausen B, Schmidt LG, Wolf B. Adverse psychic reactions to psychotropic drugs - a report from the AMÜP-study. Pharmacopsychiat 1993; 26: 84-93
16. Grohmann R, Rüther E, Schmidt LG [Hrsg]. Unerwünschte Wirkungen von Psychopharmaka - Ergebnisse der Amüp-Studie. Springer Verlag, Berlin: 1994
17. Grohmann R, Rüther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiat 1999; 32: 21-28
18. Hurwitz N. Predisposing factors in adverse reactions to drugs. Brit Med J 1969; 1: 536-539
19. Hurwitz N, Wade O. Intensive hospital monitoring of adverse reactions to drugs. Brit Med J 1969; 1: 531-536
20. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D. Comprehensive drug surveillance. JAMA 1970; 213: 1455-1460
21. Kewitz H. Unerwünschte Wirkungen von Arzneimitteln: Mechanism. Erfassung. Bedeutung. Internist 1978; 19: 357-365
22. Lenz W. Thalidomide embryopathy in Germany 1959-1961. Riss, New York: 1985: 77-83
23. Miller RR, Greenblatt DJ [Eds.]. Drug effects in hospitalized patients. Experiences of the Boston Collaborative Drug Surveillance Program 1966-1075. John Wiley and sons, New York: 1976
24. Müller-Oerlinghausen B, Schmidt LG, Grohmann R. Does drug monitoring in psychiatry provide meaningful information on the problem of cardiotoxicity of psychotropic drugs? Arzneimittelforschung 1982; 32: 889-890
25. Novartis: Leponex Fachinformation 6. Juni 2002.
26. Grohmann R, Engel RR, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results. Pharmacopsychiat 2004; 37 Suppl 1: S4-11
27. Sassim N, Grohmann R. Adverse drug reactions with clozapine and simultaneous applications of benzodiazepines. Pharmacopsychiat 1988; 21: 306-307
28. Schmidt LG, Grohmann R, Helmchen H et al. Adverse drug reactions. Acta psychiatr scand 1984; 70: 77-89
29. Schmidt LG, Müller-Oerlinghausen B. Drug safety in psychiatry - an objective for drug monitoring in phase IV. Pharmacopsychiat 1984; 17: 152-156
30. Schmidt LG, Schüssler G, Linden M, Müller-Oerlinghausen B. Impact of adverse drug reactions on treatment of psychiatric outpatients. Pharmacopsychiatry 1985; 17: 40-41
31. Schmidt LG, Dirschedl P, Grohmann R, Scherer J, Wunderlich O, Müller-Oerlinghausen B. Consistency of assessment of adverse drug reactions in psychiatric hospitals: A comparison of an algorithmic and empirical approach. Eur J Clin Pharmacol 1986; 30: 199-204
32. Schmidt LG, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H. Tolerability and safety of antidepressant drugs in psychiatric in- and out-patients assessed by two drug surveillance systems. Pharmacopsychiat 1986; 19: 288-289
33. Schmidt LG, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönhofer PS. Adverse drug reactions of first and second generation antidepressants - a critical evaluation of drug surveillance data. Br J Psychiatry 1986; 148: 38-43
34. Schmidt LG, Czerlinsky H, Stöckel M. Longitudinal assessment of psychotropic drug use in acutely-ill psychiatric inpatients. Int J Clin Pharmacol Ther Toxicol 1987; 25: 244-250
35. Schmidt LG, Lammers V, Stöckel M, Müller-Oerlinghausen B. Recent trends in prescribing psychotropic drugs at a psychiatric university hospital in Germany [1981-1984]. Pharmacopsychiat 1988; 21: 126-130
36. Schmidt LG, Grohmann R, Strauss A, Spiess-Kiefer C, Lindmeier D, Müller-Oerlinghausen B. Epidemiology of toxic delirium due to psychotropic drugs in psychiatric hospitals. Compreh Psychiat 1987; 28: 242-249
37. Seidl LG, Thornton GF, Cluff LE. Epidemiological studies of adverse drug reation. Am J Publ Health 1965; 55: 1190
38. Spieß-Kiefer C, Grohmann R, Schmidt LG, Rüther E. Severe and life-threatening adverse reactions to psychotropic drugs. Pharmacopsychiat 1988; 21: 290-292
39. Swett CP, Shader RI. Cardiac side effects and sudden death in hospitalized psychiatric patients. Dis Nerv Syst, 1977: 69-72
40. Swett C. Patterns of drug use in psychiatric inpatient wards. J Clin Psychiat 1979; 40: 464-468
41. Von Oefele K, Rüther E. Adverse drug reaction monitoring in long-term psychiatric inpatients. Pharmacopsychiatry 1985; 18: 33-34
42. Von Oefele K, Grohmann R, Rüther E. Adverse drug reactions in Combined Tricyclic and MAOI Therapy. Pharmacopsychiat 1986; 19: 243-244
43. Wastl R, Grohmann R, Rüther E. Frequency of increased serum liver-enzyme levels under treatment with neuroleptics. Pharmacopsychiatry 1986; 19: 290-291
44. Wolf B, Conradty M, Grohmann R, Rüther E, Witzgall H, Londong V. A case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associate with Doxepin use. J Clin Psychiatry 1989; 50: 99-100
45. Wolf B, Grohmann R, Biber D, Brenner PM, Rüther E. Benzodiazepine abuse and dependence in psychiatric inpatients. Pharmacopsychiatry 1989; 22: 54-60
46. Wolf B, Grohmann R, Schmidt LG, Rüther E. Psychiatric admissions due to adverse drug reactions. Compr Psychiatry 1989; 30: 534-545